Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions

Primary Membranous Nephropathy

Interventions

DRUG

ACEI/ARB+ finerenone

The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.

DRUG

ACEI/ARB+ Placebo

Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.

All Listed Sponsors

lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT06573411 - Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy | Biotech Hunter | Biotech Hunter